HYPE3 — HYPERA S/A

CNPJ 02.932.074/0001-91 · listed classes: HYPE3 · CVM code 21431

11.3P/E

1.1P/B

10.2EV/EBITDA

13.1%FCF yield

9.7%ROE 2025

8.8%ROIC 2025

P/E, P/B and EV/EBITDA priced at the session of 2026-03-12 (R$ 21.34), the first one after the 2025 filing became public on 2026-03-12 — point-in-time, not the 31 December price.

The full history, year by year

The arrow opens the path from the figure down to the line in the regulator's file. A cell with ^! carries a caveat; a dash is a withheld figure — hover for the reason. Nothing is hidden.

indicator	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE ⟶	5.2%^!	-0.9%	3.0%	3.7%	5.5%	7.2%	13.9%	11.7%	14.1%	13.7%	14.4%	14.0%	16.6%	14.9%	11.4%	9.7%
ROIC ⟶	6.7%^!	3.9%^!	5.7%	7.8%	7.5%	8.0%	8.9%	14.0%	16.2%	14.4%^!	14.8%^!	15.5%	15.4%^!	13.9%^!	9.4%^!	8.8%^!
ROA ⟶	2.6%^!	-0.5%	1.6%	2.0%	3.1%	3.8%	8.6%	8.9%	10.9%	10.4%	8.9%	7.2%	7.8%	6.8%	5.4%	4.8%
Gross margin ⟶	57.2%	60.3%	62.2%	64.5%	63.7%	74.8%	74.3%	74.5%	71.6%	63.3%	64.3%	64.0%	63.1%	63.1%	58.9%	59.0%
EBIT margin ⟶	19.4%	12.7%	19.9%	21.1%	19.4%	29.9%	32.5%	31.9%	33.0%	33.0%	32.3%	33.1%	32.9%	31.8%	24.5%	22.9%
Net margin ⟶	8.3%	-1.6%	5.3%	6.0%	8.6%	18.9%	35.7%	26.5%	30.3%	35.3%	31.7%	22.4%	22.5%	20.9%	17.9%	15.5%
Revenue growth (1y) ⟶	—	19.1%	16.5%	9.9%	9.9%	6.8%	11.2%	12.7%	6.4%	-11.5%	24.1%	45.2%	27.1%	4.9%	-6.0%	3.4%
Revenue growth (5y CAGR) ⟶	—	—	—	—	—	1.2%	-0.2%	-1.2%	-2.6%	3.5%	6.7%	13.0%	16.6%	16.3%	17.7%	13.5%
Net debt/EBITDA ⟶	0.82x	3.65x	2.56x	2.75x	2.92x	2.19x	-0.43x	-0.70x	-0.82x	-0.70x	0.53x	2.41x	2.54x	2.67x	3.64x	3.68x
Current ratio ⟶	2.57x	2.95x	2.42x	1.97x	1.61x	2.92x	3.07x	2.30x	3.04x	3.00x	3.01x	2.34x	1.63x	1.74x	1.70x	1.47x

The current year, quarter by quarter

As the company filed it in its interim report. The fourth quarter does not exist on its own in that filing — the closed year comes in the annual one, and we do not derive a Q4, so that a figure we computed never sits beside the figures the company reported. Filed on is the date the report became public, and the price is taken from it.

quarter	revenue	profit	net margin	P/E TTM	P/B	filed on
2024T1	1,826.7	388.9	21.3%	10.6	1.54	2024-04-26
2024T2	2,188.9	492.5	22.5%	10.4	1.47	2024-07-25
2024T3	1,915.9	370.5	19.3%	8.3	1.07	2024-11-13
2025T1	1,080.9	-141.1	-13.1%	16.4	1.13	2025-04-23
2025T2	2,153.9	425.4	19.8%	21.4	1.33	2025-08-06
2025T3	2,227.2	456.1	20.5%	17.9	1.21	2025-10-28
2026T1	2,017.8	346.8	17.2%	9.2	1.10	2026-04-28
2026T2	2,336.7	490.2	21.0%	8.6	1.04	2026-08-06

Full series, every quarter: GET /empresas/HYPE3/trimestres

Dividends per year

year	per share	payments
2026	R$ 0.5261	2
2025	R$ 1.1700	4
2024	R$ 1.1678	10
2023	R$ 1.2314	4
2022	R$ 1.2320	4
2021	R$ 1.2339	4
2020	R$ 1.1732	4
2019	R$ 1.0699	5

Piotroski F-Score 7/9 (2025) — what each criterion means.

Restated filings for this company

The regulator overwrites the old version; we keep both. Figures in R$ millions: first filing on the left, restatement on the right.

fiscal year	account	first filing	restated
2014	DRE 3.01	4,770.1	2,784.3
2018	BPA 1.01.01	13.4	1,578.7
2018	BPA 1.01.02	1,565.3	0.0
2017	BPA 1.01.01	1,354.7	6.8
2017	BPA 1.01.02	0.0	1,347.9
2014	DRE 3.02	-2,034.3	-886.4
2014	DRE 3.03	2,735.7	1,897.9
2010	DRE 3.01	2,886.5	2,519.0

This company appears in

Other companies in Healthcare

15 more with a page, same CVM sector — a classification of the regulator's, not ours.

AALR3 BIOM3 BLAU3 BOBR4 BPHA3 DASA3 ESPA3 FLRY3 HAPV3 KRSA3 MATD3 NATU3 ONCO3 RDOR3 SAUD3

Take this into your code

Everything on this page is also JSON: GET /empresas/HYPE3/indicadores. WEGE3 is open for testing without a key; for the rest, create a free key (200 calls/day, no card).

Price coverage: 4,137 sessions, 2010-01-04 → 2026-09-04 · methodology · how we verify

Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 11:12 UTC. If this does not match /saude, you are reading a cached copy.